eligibility_summary
Adults (≥18) with recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer, no max prior lines, platinum‑resistant may get FT538 as 2nd line. GOG PS 0–2, adequate organs, O2≥90% (PFTs>50% if done), LVEF≥40% and no recent serious CV disease. Exclude pregnancy, systemic immunosuppression/autoimmune requiring it, asthma on chronic meds, uncontrolled infection, therapy <2w (except palliative RT) or live vaccine <6w, allergy (albumin/DMSO), prior enoblituzumab, non‑malignant CNS disease, HIV or active HBV/HCV, or other safety/compliance risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 dose-escalation testing intraperitoneal FT538 (allogeneic iPSC‑derived engineered NK cell therapy) alone or with IV enoblituzumab (monoclonal IgG1 antibody). FT538 is designed with high‑affinity, non‑cleavable CD16 and IL‑15/IL‑15R signaling to enhance NK persistence and antibody‑dependent cellular cytotoxicity (ADCC). Enoblituzumab targets B7‑H3 (CD276) on tumor cells, its Fc engages NK cells to drive ADCC and may counter B7‑H3‑mediated immune inhibition. Targets/pathways: B7‑H3 on ovarian/peritoneal tumor cells, NK cell FcγRIIIa (CD16)–mediated ADCC, IL‑15 survival signaling, innate NK cytotoxicity (perforin/granzyme). Status: terminated (product withdrawn).